Open Nav

Lakewood-Amedex, Inc.

Investor awareness/business development

  • Date:Thursday, October 18
  • Time:10:30 AM - 10:45 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Lakewood-Amedex is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The Company's products and technology are covered by an extensive patent portfolio consisting of over 100 granted and/or issued patents and 4 pending patent applications covering many major pharmaceutical markets. The Company's lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and has recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU).
  • Company Website:http://www.lakewoodamedex.com/
  • Company HQ City:Sarasota
  • Company HQ Country:United States
  • Company HQ State:Florida                        
  • CEO/Top Company Official:Steve Parkinson
  • Year Founded:2006
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development :Nu-3 (Bisphosphocin class)
  • Development Phase of Primary Product:Phase II
  • Total Amount Raised to Date, In All Rounds:18M
Back